Photo: Pixabay
April 22, 2021
Chinese genome editing startup EdiGene Inc has secured 400 million yuan ($61.7 million) in a Series B+ round of financing led by private equity (PE) firm Loyal Valley Capital to advance its pipeline into clinics and to scale up the business operation.
The Series B+ round roped in new investors BioTrack Capital and Sherpa Healthcare Partners, two China-focused, healthcare venture capital (VC) companies. The firm’s existing investors including IDG Capital, Lilly Asia Venture, 3H Health Investment, Huagai Capital, Sequoia Capital China, Alwin Capital, and Kunlun Capital re-upped in the deal.
Founded in 2015, EdiGene is a clinical-stage biotech company that focuses on leveraging genome editing technologies to accelerate drug discovery and to develop novel therapeutics for a broad range of genetic diseases and cancer. The startup has established its proprietary
Hive Ventures invests in InfuseAI and 15 more deal updates from Greater China
April 6, 2021
Taiwanese machine learning startup InfuseAI has secured a $4.3 million Series A round funding led by the iPhone manufacturer Wistron Corporation, per a company statement on Tuesday.
Taiwan-based, tech-driven global VC Hive Ventures partnering Taiwan Venture Capital Group and Silicon Valley Taiwan Investment also joined the current round.
InfuseAI is gearing up to foray into the Japan market, followed by Southeast Asia.
InfuseAI, set up in 2018, offers a gamut of development and data analysis services to enterprises in fintech and manufacturing sectors. Now its flagship solution, PrimeHub is an all-in-one, on-premise machine learning (ML) platform that can help companies maximise machine learning operations (MLOps).
China Digest: Biozon, Morewis and Surreal raise fresh capital to expand operations
Photo by Henk Vrieselaar on Unsplash
March 3, 2021
Clinical mass spectrometry specialist Biozon, industrial software developer Morewis, and synthetic media startup Surreal have secured new financing to expand operations.
Biozon nets $46m Series C
Clinical mass spectrometry specialist Biozon has raked in 300 million yuan ($46 million) in its Series C round of financing led by CITIC Private Equity Funds Management (CPE), a leading alternative asset manager co-launched in 2008 by state-backed CITIC Group.
The latest round also saw participation from healthcare investment firm Sherpa Healthcare Partners and Huagai Capital, an over 15 billion yuan ($2.3 billion) fund that focuses on healthcare, TMT, and culture, per a company statement on Wednesday.
StayMyWay, a maker of contactless technology for hotels, has raised more than $3.7 million (€3 million) and is now launching a new investment round.
The Spanish company had a major win this month when Accor hired it be the exclusive provider of mobile key technology for 700,000 guest rooms at 5,000 of its properties.
StayMyWay’s technology lets hotel guests gain access to their rooms without stopping at the front desk. Guests take a picture of themselves and their passport or another identification document using their smartphone. The company uses technology to verify the guest’s identity and issue a key to a room.
streetAsia s premium subscription service Unlock your competitive advantage in a rapidly evolving landscape. Our packages come with exclusive access to archive content, data, discount on summit tickets & more. Be a part of our growing community now. SUBSCRIBE NOW
Singapore Reporter/s
In Singapore, we are looking to double our reporting team by this year-end to comprehensively cover the fast-moving world of funded startups and VC, PE & M&A deals. We want reporters who can tell our readers what is really happening in these sectors and why it matters to markets, companies and consumers. The ability to write precisely and urgently is crucial for these roles. Ideal candidates must have to ability to work in a collaborative, dynamic, and fast-changing environment. We want our new hires to be digi